HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN

Objectives: This narrative review synthesizes current evidence regarding the modulation of psilocybin responsivity by female sex hormones (estrogen, progesterone, testosterone) across the lifespan, aiming to identify molecular mechanisms, clinical implications, and critical knowledge gaps for personalized psychedelic medicine.

Methods: Databases including PubMed, ClinicalTrials.gov, and ANZCTR were searched for literature published between 2000 and 2026. Search strategies utilized combinations of terms related to psilocybin, sex hormones, the menstrual cycle, pregnancy, menopause, and premenstrual dysphoric disorder (PMDD). Peer-reviewed studies, clinical protocols, and preclinical models were evaluated. Main

Findings: Molecular data from human PET and preclinical studies suggest that estradiol may upregulate cortical 5-HT2A receptor availability, while testosterone appears to modulate serotonin transporter (SERT) expression. These pathways potentially overlap with psilocin's pharmacodynamics. Preclinical evidence from a 2025 postpartum mouse model signals a critical warning, suggesting that postpartum psilocybin administration may paradoxically amplify anxiety-like behaviors and induce long-term anhedonia in offspring. Clinically, preliminary qualitative data suggest potential microdosing efficacy in PMDD, though rigorous randomized controlled trials are needed to confirm these findings. Major data gaps persist regarding the impact of menopause and combination oral contraceptives on psychedelic experiences.

Conclusions: Mechanistic and preclinical evidence suggests that the female hormonal landscape may influence psilocybin responsivity. However, the current lack of stratified human clinical data precludes definitive dosing or timing recommendations. Integrating hormonal tracking into future psychedelic trial designs is imperative for establishing safe, personalized therapeutic frameworks.